Inhibrx Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Inhibrx Biosciences (INBX).

Price Target Range — 3 Quarters

Analyst Consensus — 4 Analysts

2Buy

2Hold

Consensus RatingBuy# Analysts4Avg. Consensus PT$198Upside to Avg. PT+107.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 24, 2026	HC Wainwright & Co.	Robert Burns	Initiate	Buy	$245
Apr 8, 2026	Stifel	Dara Azar	Initiate	Buy	$150
Aug 22, 2025	JMP Securities	Reni J. Benjamin	Maintained	Market Perform	—
May 15, 2025	JMP Securities	Reni Benjamin	Maintained	Market Perform	—
Mar 18, 2025	Citizens Capital Markets	Reni Benjamin	Maintained	Market Perform	—
Jan 22, 2025	JMP Securities	Reni Benjamin	Maintained	Market Perform	—
Jul 23, 2024	JMP Securities	Reni Benjamin	Initiate	Market Perform	—
Jan 23, 2024	JMP Securities	Reni Benjamin	Downgrade	Market Outperform→Market Perform	—
Nov 20, 2023	JMP Securities	Reni Benjamin	Maintained	Market Outperform	$27

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $245

HC Wainwright & Co. analyst Robert Burns initiates coverage on Inhibrx Biosciences (NASDAQ:INBX) with a Buy rating and announces Price Target of $245.

Benzinga Newsdesk

This Inhibrx Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday

Top Wall Street analysts changed outlook on top names. See complete rating changes, including upgrades and downgrades, on Benzinga's analyst ratings page.

Avi Kapoor

PRO
Stifel Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $150

Stifel analyst Dara Azar initiates coverage on Inhibrx Biosciences (NASDAQ:INBX) with a Buy rating and announces Price Target of $150.

Benzinga Newsdesk

PRO
JMP Securities Reiterates Market Perform on Inhibrx Biosciencesto Market Perform

JMP Securities analyst Reni J. Benjamin reiterates Inhibrx Biosciences (NASDAQ:INBX) from Market Perform to Market Perform.

Benzinga Newsdesk

PRO
JMP Securities Reiterates Market Perform on Inhibrx Biosciencesto Market Perform

JMP Securities analyst Reni Benjamin reiterates Inhibrx Biosciences (NASDAQ:INBX) from Market Perform to Market Perform.

Benzinga Newsdesk

PRO
Citizens Capital Markets Reiterates Market Perform on Inhibrx Biosciencesto Market Perform

Citizens Capital Markets analyst Reni Benjamin reiterates Inhibrx Biosciences (NASDAQ:INBX) from Market Perform to Market Perform.

Benzinga Newsdesk

Inhibrx Biosciences Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Inhibrx Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $245

This Inhibrx Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday

PRO
Stifel Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $150

PRO
JMP Securities Reiterates Market Perform on Inhibrx Biosciencesto Market Perform

PRO
JMP Securities Reiterates Market Perform on Inhibrx Biosciencesto Market Perform

PRO
Citizens Capital Markets Reiterates Market Perform on Inhibrx Biosciencesto Market Perform

People Also Watch

People Also Watch

Inhibrx Biosciences Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Inhibrx Biosciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $245

This Inhibrx Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday

PROStifel Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $150

PROJMP Securities Reiterates Market Perform on Inhibrx Biosciencesto Market Perform

PROJMP Securities Reiterates Market Perform on Inhibrx Biosciencesto Market Perform

PROCitizens Capital Markets Reiterates Market Perform on Inhibrx Biosciencesto Market Perform

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $245

PRO
Stifel Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $150

PRO
JMP Securities Reiterates Market Perform on Inhibrx Biosciencesto Market Perform

PRO
JMP Securities Reiterates Market Perform on Inhibrx Biosciencesto Market Perform

PRO
Citizens Capital Markets Reiterates Market Perform on Inhibrx Biosciencesto Market Perform